Carisma Therapeutics Inc
NASDAQ:CARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Square Enix Holdings Co Ltd
OTC:SQNXF
|
JP |
|
Husqvarna AB
STO:HUSQ B
|
SE |
|
STO Express Co Ltd
SZSE:002468
|
CN |
|
D
|
Dingzing Advanced Materials Inc
TWSE:6585
|
TW |
|
Petpal Pet Nutrition Technology Co Ltd
SZSE:300673
|
CN |
|
H
|
Hardwyn India Ltd
NSE:HARDWYN
|
IN |
|
L
|
Lens Technology Co Ltd
SZSE:300433
|
CN |
Carisma Therapeutics Inc
Depreciation & Amortization
Carisma Therapeutics Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Carisma Therapeutics Inc
NASDAQ:CARM
|
Depreciation & Amortization
$2.1m
|
CAGR 3-Years
272%
|
CAGR 5-Years
65%
|
CAGR 10-Years
18%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$209.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$543.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Carisma Therapeutics Inc
Glance View
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2014-02-06. The firm is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The firm's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.
See Also
What is Carisma Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
2.1m
USD
Based on the financial report for Jun 30, 2025, Carisma Therapeutics Inc's Depreciation & Amortization amounts to 2.1m USD.
What is Carisma Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
18%
Over the last year, the Depreciation & Amortization growth was -39%. The average annual Depreciation & Amortization growth rates for Carisma Therapeutics Inc have been 272% over the past three years , 65% over the past five years , and 18% over the past ten years .
